A magnetic bead-based protein kinase assay with dual detection techniques

Analytical Biochemistry

Volumn 408, Issue 1, 2011, Pages 5-11

  Zhou, Guangchang ^a   Sylvester, Juliesta E ^a   Wu, Ding ^a   Veach, Darren R ^b   Kron, Stephen J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunochemifluorescence; Inhibitors; Kinase assays; Magnetic beads; MALDI TOF mass spectrometry; Protein phosphorylation

Indexed keywords

CORROSION INHIBITORS; ENZYMES; INDUCTIVELY COUPLED PLASMA; MAGNETISM; MASS SPECTROMETRY; PHOSPHORYLATION;

IMMUNOCHEMIFLUORESCENCE; KINASE ASSAYS; MAGNETIC BEADS; MALDI-TOF MASS SPECTROMETRY; PROTEIN PHOSPHORYLATION;

CHEMICAL DETECTION;

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ABELSON KINASE; BIOTIN; DASATINIB; IMATINIB; PD 173952; PD 173956; PD 173958; PEPTIDE; PROTEIN TYROSINE KINASE INHIBITOR; STREPTAVIDIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; IC 50; IMMUNOFLUORESCENCE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN IMMOBILIZATION; PROTEIN PHOSPHORYLATION;

EID: 77958484582     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.08.034     Document Type: Article

References (56)

1. Pawson T., Scott J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997, 278:2075-2080.
2. Hunter T. Signaling-2000 and beyond. Cell 2000, 100:113-127.
3. Hunter T. Protein-kinases and phosphatases-the yin and yang of protein-phosphorylation and signaling. Cell 1995, 80:225-236.
4. Demichelis F., Setlur S.R., Beroukhim R., Perner S., Korbel J.O., LaFargue C.J., Pflueger D., Pina C., Hofer M.D., Sboner A., Svensson M.A., Rickman D.S., Urban A., Snyder M., Meyerson M., Lee C., Gerstein M.B., Kuefer R., Rubin M.A. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009, 48:366-380.
5. Alonso A., Sasin J., Bottini N., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
6. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
7. Zhang J.M., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.
8. Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287:1969-1973.
9. Varmus H. The new era in cancer research. Science 2006, 312:1162-1165.
10. Thompson C.B. Attacking cancer at its root. Cell 2009, 138:1051-1054.
11. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2:561-566.
12. Collins I., Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2006, 2:689-700.
13. Rix U., Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 2009, 5:616-624.
14. Zhu H., Bilgin M., Bangham R., Hall D., Casamayor A., Bertone P., Lan N., Jansen R., Bidlingmaier S., Houfek T., Mitchell T., Miller P., Dean R.A., Gerstein M., Snyder M. Global analysis of protein activities using proteome chips. Science 2001, 293:2101-2105.
15. Zhu H., Snyder M. Protein arrays and microarrays. Curr. Opin. Chem. Biol. 2001, 5:40-45.
16. Greis K.D. Mass spectrometry for enzyme assays and inhibitor screening: an emerging application in pharmaceutical research. Mass Spectrom. Rev. 2007, 26:324-339.
17. Inamori K., Kyo M., Nishiya Y., Inoue Y., Sonoda T., Kinoshita E., Koike T., Katayama Y. Detection and quantification of on-chip phosphorylated peptides by surface plasmon resonance imaging techniques using a phosphate capture molecule. Anal. Chem. 2005, 77:3979-3985.
18. Mori T., Inamori K., Inoue Y., Han X., Yamanouchi G., Niidome T., Katayama Y. Evaluation of protein kinase activities of cell lysates using peptide microarrays based on surface plasmon resonance imaging. Anal. Biochem. 2008, 375:223-231.
19. Han X., Shigaki S., Yamaji T., Yarnanouchi G., Mori T., Niidome T., Katayama Y. A quantitative peptide array for evaluation of protein kinase activity. Anal. Biochem. 2008, 372:106-115.
20. Shults M.D., Kozlov I.A., Nelson N., Kermani B.G., Melnyk P.C., Shevchenko V., Srinivasan A., Musmacker J., Hachmann J.P., Barker D.L., Lebl M., Zhao C.F. A multiplexed protein kinase assay. ChemBioChem 2007, 8:933-942.
21. Bernsteel D.J., Roman D.L., Neubig R.R. In vitro protein kinase activity measurement by flow cytometry. Anal. Biochem. 2008, 383:180-185.
22. Houseman B.T., Huh J.H., Kron S.J., Mrksich M. Peptide chips for the quantitative evaluation of protein kinase activity. Nat. Biotechnol. 2002, 20:270-274.
23. Kim Y.P., Oh E., Oh Y.H., Moon D.W., Lee T.G., Kim H.S. Protein kinase assay on peptide-conjugated gold nanoparticles by using secondary-ion mass spectrometric imaging. Angew. Chem. Int. Ed. 2007, 46:6816-6819.
24. Oishi J., Han X., Kang J.H., Asami Y., Mori T., Niidorne T., Katayarna Y. High-throughput colorimetric detection of tyrosine kinase inhibitors based on the aggregation of gold nanoparticles. Anal. Biochem. 2008, 373:161-163.
25. Wu D., Mand M.R., Veach D.R., Parker L.L., Clarkson B., Kron S.J. A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. Anal. Biochem. 2008, 375:18-26.
26. Wu D., Nair-Gill E., Sher D.A., Parker L.L., Campbell J.M., Siddiqui M., Stock W., Kron S.J. Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. Anal. Biochem. 2005, 347:67-76.
27. Brueggemeier S.B., Wu D., Kron S.J., Palecek S.P. Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules 2005, 6:2765-2775.
28. Parker L.L., Brueggemeier S.B., Rhee W.J., Wu D., Kent S.B.H., Kron S.J., Palecek S.P. Photocleavable peptide hydrogel arrays for MALDI-TOF analysis of kinase activity. Analyst 2006, 131:1097-1104.
29. Kinumi T., Niki E., Shigeri Y., Matsumoto H. Affinity-tagged phosphorylation assay by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (ATPA-MALDI): application to calcium/calmodulin-dependent protein kinase. J. Biochem. 2005, 138:791-796.
30. Akita S., Umezawa N., Kato N., Higuchi T. Array-based fluorescence assay for serine/threonine kinases using specific chemical reaction. Bioorg. Med. Chem. 2008, 16:7788-7794.
31. Greis K.D., Zhou S.T., Burt T.M., Carr A.N., Dolan E., Easwaran V., Evdokimov A., Kawamoto R., Roesgen J., Davis G.F. MALDI-TOF MS as a label-free approach to rapid inhibitor screening. J. Am. Soc. Mass Spectrom. 2006, 17:815-822.
32. Rathore R., Corr J., Scott G., Vollmerhaus P., Greis K.D. Development of an inhibitor screening platform via mass spectrometry. J. Biomol. Screen. 2008, 13:1007-1013.
33. McLachlin D.T., Chait B.T. Analysis of phosphorylated proteins and peptides by mass spectrometry. Curr. Opin. Chem. Biol. 2001, 5:591-602.
34. Lundeberg J., Pettersson B., Uhlen M. Direct DNA sequencing of polymerase chain reaction products using magnetic beads. The Nucleic Acid Protocols Handbook 2000, 523-531. Humana Press Inc., USA. R. Rapley (Ed.).
35. Ficarro S.B., Adelmant G., Tomar M.N., Zhang Y., Cheng V.J., Marto J.A. Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. Anal. Chem. 2009, 81:4566-4575.
36. Hsiao H.H., Hsieh H.Y., Chou C.C., Lin S.Y., Wang A.H.J., Khoo K.H. Concerted experimental approach for sequential mapping of peptides and phosphopeptides using c18-functionalized magnetic nanoparticles. J. Proteome Res. 2007, 6:1313-1324.
37. Li Y.C., Lin Y.S., Tsai P.J., Chen C.T., Chen W.Y., Chen Y.C. Nitrilotriacetic acid-coated magnetic nanoparticles as affinity probes for enrichment of histidine-tagged proteins and phosphorylated peptides. Anal. Chem. 2007, 79:7519-7525.
38. Klutchko S.R., Hamby J.M., Boschelli D.H., Wu Z.P., Kraker A.J., Amar A.M., Hartl B.G., Shen C., Klohs W.D., Steinkampf R.W., Driscoll D.L., Nelson J.M., Elliott W.L., Roberts B.J., Stoner C.L., Vincent P.W., Dykes D.J., Panek R.L., Lu G.H., Major T.C., Dahring T.K., Hallak H., Bradford L.A., Showalter H.D.H., Doherty A.M. 2-Substituted aminopyrido 2,3-d pyrimidin-7(8H) ones: structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. 1998, 41:3276-3292.
39. Boschelli D.H., Wu Z.P., Klutchko S.R., Showalter H.D.H., Hamby J.M., Lu G.H., Major T.C., Dahring T.K., Batley B., Panek R.L., Keiser J., Hartl B.G., Kraker A.J., Klohs W.D., Roberts B.J., Patmore S., Elliott W.L., Steinkampf R., Bradford L.A., Hallak H., Doherty A.M. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido 2,3-d pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J. Med. Chem. 1998, 41:4365-4377.
40. Kang J.H., Katayama Y., Han A.S., Shigaki S., Oishi J., Kawamura K., Toita R., Han X.M., Mori T., Niidome T. Mass-tag technology responding to intracellular signals as a novel assay system for the diagnosis of tumor. J. Am. Soc. Mass Spectrom. 2007, 18:106-112.
41. Kang J.H., Toita R., Oishi J., Niidome T., Katayama Y. Effect of the addition of diammonium citrate to alpha-cyano-4-hydroxycinnamic acid (CHCA) matrix for the detection of phosphorylated peptide in phosphorylation reactions using cell and tissue lysates. J. Am. Soc. Mass Spectrom. 2007, 18:1925-1931.
42. Zhou S., Carraway K.L., Eck M.J., Harrison S.C., Feldman R.A., Mohammadi M., Schlessinger J., Hubbard S.R., Smith D.P., Eng C., Lorenzo M.J., Ponder B.A.J., Mayer B.J., Cantley L.C. Catalytic specificity of protein-tyrosine kinases is critical for selective signaling. Nature 1995, 373:536-539.
43. Inamori K., Kyo M., Matsukawa K., Inoue Y., Sonoda T., Tatematsu K., Tanizawa K., Mori T., Katayama Y. Optimal surface chemistry for peptide immobilization in on-chip phosphorylation analysis. Anal. Chem. 2008, 80:643-650.
44. Parker L., Engel-Hall A., Drew K., Steinhardt G., Helseth D.L., Jabon D., McMurry T., Angulo D.S., Kron S.J. Investigating quantitation of phosphorylation using MALDI-TOF mass spectrometry. J. Mass Spectrom. 2008, 43:518-527.
45. Kang J.H., Kuramoto M., Tsuchiya A., Toita R., Asai D., Sato Y.T., Mori T., Niidome T., Katayama Y. Correlation between phosphorylation ratios by matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis and enzyme kinetics. Eur. J. Mass Spectrom. 2008, 14:261-265.
46. Wu D., Sylvester J.E., Parker L.L., Zhou G., Kron S.J. Peptide reporters of kinase activity in whole cell lysates. Biopolymers (Pept. Sci.) 2010, 94:475-486.
47. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
48. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., Lydon N.B. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56:100-104.
49. Huron D.R., Gorre M.E., Kraker A.J., Sawyers C.L., Rosen N., Moasser M.M. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-Abl-driven K562 cells and is effective against STI571-resistant Bcr-Abl mutants. Clin. Cancer Res. 2003, 9:1267-1273.
50. Min D.H., Su J., Mrksich M. Profiling kinase activities by using a peptide chip and mass spectrometry. Angew. Chem. Int. Ed. 2004, 43:5973-5977.
51. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., Mathieson T., Perrin J., Raida M., Rau C., Reader V., Sweetman G., Bauer A., Bouwmeester T., Hopf C., Kruse U., Neubauer G., Ramsden N., Rick J., Kuster B., Drewes G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25:1035-1044.
52. O'Hare T., Walters D.K., Stoffregen E.P., Jia T.P., Manley P.W., Mestan J., Cowan-Jacob S.W., Lee F.Y., Heinrich M.C., Deininger M.W.N., Druker B.J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65:4500-4505.
53. Brasher B.B., Van Etten R.A. C-Ab1 has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 2000, 275:35631-35637.
54. Rix U., Hantschel O., Duernberger G., Rix L.L.R., Planyavsky M., Fernbach N.V., Kaupe I., Bennett K.L., Valent P., Colinge J., Kocher T., Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets. Blood 2007, 110:4055-4063.
55. Hantschel O., Rix U., Schmidt U., Burckstummer T., Kneidinger M., Schutze G., Colinge J., Bennett K.L., Ellmeier W.R., Valent P., Superti-Furga G. The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib. Proc. Natl. Acad. Sci. USA 2007, 104:13283-13288.
56. von Bubnoff N., Veach D.R., Miller W.T., Li W.Q., Peschel C., Bornmann W.G., Clarkson B., Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res. 2003, 63:6395-6404.